GlassScriptPhysician profile
Charles C Sung
NPI 1275532996
$1,146.27
in general payments reported to CMS, 2019-2025
15 companies · $171 in 2025
The $171 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $152 · 2020: $113 · 2021: $160 · 2022: $306 · 2023: $151 · 2024: $93.66 · 2025: $171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $415.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $415.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $251.09 | 2022-2023 | Durysta, Alphagan P, Vuity |
| Allergan, INC. | $175.21 | 2020-2021 | |
| Quidel Corporation | $133.60 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $103.93 | 2024-2025 | Xdemvy |
| Genentech USA, INC. | $103.22 | 2022-2024 | Vabysmo |
| Biogen, INC. | $75.05 | 2022-2024 | Byooviz |
| Harrow Eye, LLC | $68.77 | 2025 | Iheezo |
| Eyepoint US, INC. | $59.89 | 2021-2023 | |
| Astellas Pharma US INC | $46.36 | 2024-2025 | Izervay |
| Novartis Pharmaceuticals Corporation | $44.15 | 2021 | |
| Bausch & Lomb Americas INC. | $23.13 | 2022 | |
| Optos, INC. | $17.93 | 2019 | |
| Aerie Pharmaceuticals, INC. | $14.85 | 2021 | |
| Apellis Pharmaceuticals, INC. | $14.77 | 2023 | Syfovre |
| Alcon Vision LLC | $14.32 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Sung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.